ClassID:

96744

C07K7/16 - CPC Classification

Classification description:

Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof; Linear peptides containing only normal peptide links Oxytocins; Vasopressins; Related peptides

Recent Application in this class:
#1
20260015389
2026-01-15

V1A Receptor Partial Agonist and Method of Use

#2
20250281567
2025-09-11

DESMOPRESSIN ORAL COMPOSITIONS

#3
20250090623
2025-03-20

DESMOPRESSIN ORAL COMPOSITIONS

#4
20240335501
2024-10-10

Desmopressin oral compositions

#5
20240301004
2024-09-12

LABELED OXYTOCIN AND METHOD OF MANUFACTURE AND USE

#6
20230399360
2023-12-14

TERLIPRESSIN-OCTADECANEDIOIC ACID CONJUGATE FOR VASOCONSTRICTIVE THERAPY

#7
20230357322
2023-11-09

Method of manufacturing a pharmaceutical composition

#8
20230322886
2023-10-12

RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN

#9
20230322872
2023-10-12

RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN

#10
20230265124
2023-08-24

OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME

#11
20230248800
2023-08-10

V1A Receptor Partial Agonist and Method of Use

#12
20230173076
2023-06-08

METABOLICALLY STABLE PEPTIDE ANALOGS

#13
20220408722
2022-12-29

METHOD FOR INCREASING LONGEVITY AND/OR BUD OPENING OF CUT FLOWERS

#14
20220213139
2022-07-07

MANUFACTURE OF DISULFIDE BONDED PEPTIDES

#15
20220152145
2022-05-19

Method and formulation for inhalation

#16
20210309699
2021-10-07

Method of manufacturing a pharmaceutical composition

#17
20210002331
2021-01-07

Labeled oxytocin and method of manufacture and use

#18
20200330432
2020-10-22

THERAPEUTICS FOR PRETERM LABOR MANAGEMENT

#19
20200255475
2020-08-13

Metabolite inspired selective oxytocin receptor agonists

#20
20200216500
2020-07-09

Method of manufacturing a pharmaceutical composition

#21
20200002382
2020-01-02

Method for manufacturing oxytocin by liquid-phase polypeptide synthesis

#22
20190328887
2019-10-31

METABOLICALLY STABLE PEPTIDE ANALOGS

#23
20190194257
2019-06-27

Vasopressin-2 receptor agonists

#24
20190194246
2019-06-27

SOLID PHASE PEPTIDE SYNTHESIS

#25
20190135859
2019-05-09

METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION

#26
20180360806
2018-12-20

Therapeutics for preterm labor management

#27
20180282367
2018-10-04

NEW METHODS FOR MAKING BARUSIBAN AND ITS INTERMEDIATES

#28
20180252732
2018-09-06

Method of obtaining a binder to prepro-vasopressin or fragments thereof

#29
20180215784
2018-08-02

METHOD FOR PREPARATION OF N-ACYL PEPTIDES, POLYPEPTIDES AND PROTEINS

#30
20170304456
2017-10-26

FAST DISSOLVING PHARMACEUTICAL COMPOSITION

#31
20170226152
2017-08-10

Solid phase peptide synthesis

#32
20170224762
2017-08-10

Method and formulation for inhalation

#33
20170081368
2017-03-23

PEPTIDES AS OXYTOCIN AGONISTS

#34
20160304459
2016-10-20

NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR

#35
20150307578
2015-10-29

Composition for long-acting peptide analogs

#36
20150307555
2015-10-29

Vasopressin-2 receptor agonists

#37
20150293127
2015-10-15

Arginine vasopressin pro-hormone as predictive biomarker for diabetes

#38
20150284434
2015-10-08

Peptides as oxytocin agonists

#39
20150126432
2015-05-07

V1a receptor agonists

#40
20150045300
2015-02-12

Fast dissolving pharmaceutical composition

#41
20140335628
2014-11-13

METHOD OF OBTAINING A BINDER TO PREPRO-VASOPRESSIN OR FRAGMENTS THEREOF

#42
20140051628
2014-02-20

Composition for long-acting peptide analogs

#43
20140017808
2014-01-16

Prognosis and risk assessment in stroke patients by determining the level of marker peptides

#44
20130261285
2013-10-03

Method for preparing atosiban acetate

#45
20130164372
2013-06-27

Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

#46
20120214733
2012-08-23

Oxytocin receptor agonists

#47
20120196808
2012-08-02

Peptidic vasopressin receptor agonists

#48
20120178900
2012-07-12

CHROMATOGRAPHIC PROCESSES AND PURIFIED COMPOUNDS THEREOF

#49
20120094910
2012-04-19

IMPROVED PROCESS FOR THE PREPARATION OF DESMOPRESSIN OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

#50
20110318766
2011-12-29

Arginine vasopressin pro-hormone as predictive biomarker for diabetes

#51
20110263821
2011-10-27

PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES

#52
20110263818
2011-10-27

Peptidic Constructs with Amino Acid Surrogates

#53
20110237494
2011-09-29

Use of peptidic vasopression receptor agonists

#54
20110207662
2011-08-25

Composition for long-acting peptide analogs

#55
20110044905
2011-02-24

Oxytocin analogues

#56
20100240865
2010-09-23

PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES

#57
20100137559
2010-06-03

PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES

#58
20090305959
2009-12-10

Use of peptidic vasopressin receptor agonists

#59
20090275522
2009-11-05

Compounds

#60
20090088387
2009-04-02

Composition for long-acting peptide analogs

#61
20090069224
2009-03-12

Linear and cyclic melanocortin receptor-specific peptidomimetics

#62
20090054309
2009-02-26

Peptidic vasopressin receptor agonists

#63
20080177035
2008-07-24

Methods for making intermediates and oxytocin analogues

#64
20070260040
2007-11-08

Amino acid surrogates for peptidic constructs

#65
20070010655
2007-01-11

Stationary phases and a purification process using the stationary phases

#66
20060247157
2006-11-02

Methods for making intermediates and oxytocin analogues

#67
20060148699
2006-07-06

Counterion exchange process for peptides

#68
20060040857
2006-02-23

1-desamino-8-D-arginyl vasopressin analogs

#69
20060014933
2006-01-19

Using amines or amino acids as mobile phase modifiers in chromatography